Clinical Trial Update: A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes [Phase 1]

View source ↗

Summary

A completed Phase 1 multiple-dose trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of the diabetes drug candidate NNC0123-0000-0338…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NNC0123-0000-0338

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED